By lowering LDL cholesterol levels and modulating vascular dynamics, PCSK9 inhibitors alleviate hemodynamic disturbances in portal hypertension, potentially enhancing liver circulation and reducing intrahepatic vascular resistance [261]. Here, PCSK9 is linked to portal hypertension.